Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children

Inclusion Criteria: * Subjects who the investigator believes that parent(s)/Legally Acceptable Representatives (LAR) can and will comply with the requirements of the protocol. * A male or female between, and including, 13 and 15 months of age at the time of the first vaccination. * Written informed consent obtained from the parent(s)/ LAR of the subject. * Healthy subjects as established by medical history and clinical examination before entering into the study. Exclusion Criteria: * Child in care. * Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the dose of study vaccine, or planned use during the study period. * Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. * Planned administration/ administration of a vaccine not foreseen by the study protocol starting 30 days prior to the study vaccination/s and ending 42 days after the vaccination/s (at Visit 2), with the exception of inactivated influenza (flu) vaccine, which may be given at any time during the study, including the day of study vaccination/s. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. * Previous vaccination against measles, mumps, rubella, varicella/ herpes zoster and/or N. meningitidis serogroup C. * History of measles, mumps, rubella, varicella and/or N. meningitidis serogroup C diseases. * Known exposure to measles, mumps, rubella and or varicella starting 30 days prior to enrolment. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * Family history of congenital or hereditary immunodeficiency. * History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s). * Major congenital defects or serious chronic illness. * Acute disease and/or fever at the time of enrollment. * Documented human immunodeficiency virus (HIV) positive subject. * Any contraindications as stated in the Summary of Product Characteristics. * Administration of immunoglobulins and/or any blood products within three months prior to the first vaccine dose or planned administration during the study period.